HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia.

AuthorsM Bocchia, E Abruzzese, F Forconi, M Ippoliti, M M Trawinska, M T Pirrotta, D Raspadori, M Tozzi, A Gozzetti, F Lauria
JournalLeukemia (Leukemia) Vol. 20 Issue 1 Pg. 142-3 (Jan 2006) ISSN: 0887-6924 [Print] England
PMID16281064 (Publication Type: Letter, Research Support, Non-U.S. Gov't)
Chemical References
  • Benzamides
  • Interferon-alpha
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
Topics
  • Adolescent
  • Adult
  • Benzamides
  • CD4-Positive T-Lymphocytes (drug effects, immunology)
  • Child
  • Drug Screening Assays, Antitumor
  • Humans
  • Imatinib Mesylate
  • Immunity, Cellular (drug effects)
  • Immunization
  • Interferon-alpha (therapeutic use)
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy)
  • Piperazines (therapeutic use)
  • Pyrimidines (therapeutic use)
  • T-Lymphocytes (drug effects, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: